EUVIMEDEUVIMED entdecken
Crossref

Safety of Transarterial Liver Directed Therapy for Metastatic Neuroendocrine Tumor for Patients with Carcinoid Heart Disease

MD Jason Kim,, MD Nicholas Fidelman,, MD, Emily Bergsland,, MD Kirsten Tolstrup,, Etay Ziv,, MD Erica Alexander,, Aguirre, MD Adrian Gonzalez

Endocrine Abstracts · 04.03.2026

DOI: 10.1530/endoabs.116.c25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine Abstracts, online erschienen am 04.03.2026. Verfasst von MD Jason Kim, und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kim,, M. J., Fidelman,, M. N., MD, Bergsland,, E., Tolstrup,, M. K., Ziv,, E., Alexander,, M. E., Aguirre, & Gonzalez, M. A. (2026). Safety of Transarterial Liver Directed Therapy for Metastatic Neuroendocrine Tumor for Patients with Carcinoid Heart Disease. Endocrine Abstracts. https://doi.org/10.1530/endoabs.116.c25

Vancouver

Kim, MJ, Fidelman, MN, MD, Bergsland, E, Tolstrup, MK, Ziv, E, et al. Safety of Transarterial Liver Directed Therapy for Metastatic Neuroendocrine Tumor for Patients with Carcinoid Heart Disease. Endocrine Abstracts. 2026. doi:10.1530/endoabs.116.c25

BibTeX
@article{Kim2026,
  author = {Kim,, MD Jason and Fidelman,, MD Nicholas and MD and Bergsland,, Emily and Tolstrup,, MD Kirsten and Ziv,, Etay and Alexander,, MD Erica and Aguirre and Gonzalez, MD Adrian},
  title = {Safety of Transarterial Liver Directed Therapy for Metastatic Neuroendocrine Tumor for Patients with Carcinoid Heart Disease},
  journal = {Endocrine Abstracts},
  year = {2026},
  doi = {10.1530/endoabs.116.c25}
}
Kostenlos starten →